There was a 48% lower incidence of composite IBD-related outcomes (defined as the need for oral corticosteroids, TNF-α inhibitors, IBD-related hospitalization, or surgery) among patients on GLP-1-based therapies (adjusted incidence rate ratio [IRR]: 0.52, 95% CI: 0.42–0.65). This evidence concerns the gene GLP1R and inflammatory bowel disease.